# FKTN

## Overview
The FKTN gene encodes the protein fukutin, a type II membrane protein primarily localized in the Golgi apparatus, where it functions as a ribitol 5-phosphate transferase. Fukutin is integral to the glycosylation of α-dystroglycan, a process essential for the structural integrity and function of muscle cell membranes. This glycosylation is crucial for the interaction of α-dystroglycan with extracellular matrix components, such as laminin, thereby maintaining the dystrophin-glycoprotein complex that links the intracellular cytoskeleton to the extracellular matrix (Gaertner2022Compound; Beedle2012Mouse). Mutations in the FKTN gene are associated with various muscular dystrophies, collectively known as dystroglycanopathies, which include conditions such as Fukuyama congenital muscular dystrophy and Walker-Warburg syndrome (Murakami2006Fukutin; Silan2003A). These disorders highlight the critical role of fukutin in muscle and cardiac health, as well as its broader implications in human disease.

## Structure
Fukutin (FKTN) is a protein encoded by the FKTN gene, playing a crucial role in glycosylation processes. The primary structure of fukutin consists of a specific sequence of amino acids, which determines its function and interaction with other molecules. The secondary structure of fukutin may include alpha helices and beta sheets, contributing to its stability and functional conformation. The tertiary structure refers to the three-dimensional conformation of fukutin, which is essential for its biological activity and interaction with other cellular components. The quaternary structure involves the assembly of fukutin with other proteins, which can be critical for its role in glycosylation pathways.

Post-translational modifications of fukutin can significantly impact its function and localization within the cell. These modifications may include phosphorylation, glycosylation, or other chemical changes that alter the protein's activity or stability. Splice variant isoforms of fukutin can also exist, potentially leading to differences in its function or expression patterns. These structural and functional variations are important for understanding the diverse roles of fukutin in cellular processes and its implications in human health and disease.

## Function
The FKTN gene encodes the protein fukutin, which plays a critical role in the glycosylation of α-dystroglycan, a process essential for muscle cell membrane stability and function. Fukutin is a type II membrane protein localized in the Golgi apparatus, where it acts as a ribitol 5-phosphate transferase. This enzyme uses cytidine diphosphate (CDP)-ribitol to generate a ribitol 5-phosphate tandem structure, which is crucial for the proper glycosylation of α-dystroglycan (Gaertner2022Compound). Proper glycosylation of α-dystroglycan is necessary for its interaction with extracellular matrix components such as laminin, which is vital for maintaining the integrity of the dystrophin-glycoprotein complex. This complex connects the intracellular cytoskeleton to the extracellular matrix, ensuring structural stability and cell signaling in muscle tissues (Beedle2012Mouse).

In cardiomyocytes, fukutin is crucial for maintaining contractile function and calcium handling during excitation-contraction coupling. It also plays a significant role in maintaining the integrity of the Golgi-derived microtubule network, which is essential for proper protein and lipid trafficking to the plasma membrane (Ujihara2019Elimination).

## Clinical Significance
Mutations in the FKTN gene, which encodes the protein fukutin, are associated with a range of muscular dystrophies known as dystroglycanopathies. These conditions are characterized by defects in the glycosylation of α-dystroglycan, a crucial component for cell membrane stability. The most notable condition linked to FKTN mutations is Fukuyama congenital muscular dystrophy (FCMD), prevalent in Japan due to a founder mutation. FCMD is marked by severe muscle wasting, hypotonia, and mental retardation from early infancy, often accompanied by brain malformations and eye abnormalities (Murakami2006Fukutin; Toda2000The).

FKTN mutations can also lead to Walker-Warburg syndrome (WWS), a severe form of congenital muscular dystrophy with brain and eye anomalies, and muscle-eye-brain disease (MEB) (Silan2003A; Yis2011Fukutin). In non-Japanese populations, FKTN mutations have been identified in patients with milder conditions such as limb-girdle muscular dystrophy (LGMD) and dilated cardiomyopathy (DCM) without intellectual disability (Yis2011Fukutin; Gaertner2022Compound). The severity of these conditions often correlates with the type of mutation, with nonsense mutations typically resulting in more severe phenotypes (Gaertner2022Compound).

## Interactions
Fukutin (FKTN) is involved in several critical interactions within the cell, particularly related to its role in glycosylation processes. FKTN is essential for the glycosylation of α-dystroglycan, a component of the dystrophin-glycoprotein complex, which is crucial for maintaining the structural integrity of muscle cells. This interaction is vital for linking the intracellular cytoskeleton to the extracellular matrix, facilitating proper muscle function and cellular signaling (Ujihara2019Elimination; Gaertner2022Compound).

FKTN also interacts with other Golgi-resident glycosyltransferases, forming complexes that impact cellular glycosylation and the structure of the Golgi apparatus. This interaction is significant for maintaining the integrity of the Golgi-derived microtubule network in cardiomyocytes, which is crucial for proper cardiac function (Ujihara2019Elimination).

In the context of cardiac health, FKTN is involved in maintaining contractile function and calcium handling during excitation-contraction coupling in cardiomyocytes. Its deficiency leads to altered calcium signaling, contributing to cardiac dysfunction and hypertrophic remodeling (Ujihara2019Elimination). These interactions highlight the multifaceted role of FKTN in cellular processes and its importance in maintaining muscle and cardiac health.


## References


[1. (Yis2011Fukutin) Uluc Yis, Gökhan Uyanik, Pinar Bambul Heck, Martin Smitka, Hannes Nobel, Friedrich Ebinger, Eray Dirik, Lucy Feng, Semra H. Kurul, Katja Brocke, Aycan Unalp, Erdener Özer, Handan Cakmakci, Caroline Sewry, Sebahattin Cirak, Francesco Muntoni, Ute Hehr, and Deborah J. Morris-Rosendahl. Fukutin mutations in non-japanese patients with congenital muscular dystrophy: less severe mutations predominate in patients with a non-walker-warburg phenotype. Neuromuscular Disorders, 21(1):20–30, January 2011. URL: http://dx.doi.org/10.1016/j.nmd.2010.08.007, doi:10.1016/j.nmd.2010.08.007. This article has 29 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.nmd.2010.08.007)

[2. (Beedle2012Mouse) Aaron M. Beedle, Amy J. Turner, Yoshiaki Saito, John D. Lueck, Steven J. Foltz, Marisa J. Fortunato, Patricia M. Nienaber, and Kevin P. Campbell. Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy. Journal of Clinical Investigation, 122(9):3330–3342, September 2012. URL: http://dx.doi.org/10.1172/jci63004, doi:10.1172/jci63004. This article has 57 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1172/jci63004)

[3. (Toda2000The) Tatsushi Toda, Kazuhiro Kobayashi, Eri Kondo-Iida, Junko Sasaki, and Yusuke Nakamura. The fukuyama congenital muscular dystrophy story. Neuromuscular Disorders, 10(3):153–159, March 2000. URL: http://dx.doi.org/10.1016/s0960-8966(99)00109-1, doi:10.1016/s0960-8966(99)00109-1. This article has 76 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/s0960-8966(99)00109-1)

[4. (Murakami2006Fukutin) Terumi Murakami, Yukiko K. Hayashi, Satoru Noguchi, Megumu Ogawa, Ikuya Nonaka, Yuzo Tanabe, Mieko Ogino, Fumio Takada, Makoto Eriguchi, Norihiko Kotooka, Kevin P. Campbell, Makiko Osawa, and Ichizo Nishino. Fukutin gene mutations cause dilated cardiomyopathy with minimal muscle weakness. Annals of Neurology, 60(5):597–602, October 2006. URL: http://dx.doi.org/10.1002/ana.20973, doi:10.1002/ana.20973. This article has 126 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.20973)

[5. (Silan2003A) Fatma Silan, Mieko Yoshioka, Kazuhiro Kobayashi, Enver Simsek, Murat Tunc, Murat Alper, Meryem Cam, Aysel Guven, Yoji Fukuda, Moritoshi Kinoshita, Kenan Kocabay, and Tatsushi Toda. A new mutation of the fukutin gene in a non‐japanese patient. Annals of Neurology, 53(3):392–396, February 2003. URL: http://dx.doi.org/10.1002/ana.10491, doi:10.1002/ana.10491. This article has 86 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1002/ana.10491)

[6. (Gaertner2022Compound) Anna Gaertner, Lidia Burr, Baerbel Klauke, Andreas Brodehl, Kai Thorsten Laser, Karin Klingel, Jens Tiesmeier, Uwe Schulz, Edzard zu Knyphausen, Jan Gummert, and Hendrik Milting. Compound heterozygous fktn variants in a patient with dilated cardiomyopathy led to an aberrant α-dystroglycan pattern. International Journal of Molecular Sciences, 23(12):6685, June 2022. URL: http://dx.doi.org/10.3390/ijms23126685, doi:10.3390/ijms23126685. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms23126685)

[7. (Ujihara2019Elimination) Yoshihiro Ujihara, Motoi Kanagawa, Satoshi Mohri, Satomi Takatsu, Kazuhiro Kobayashi, Tatsushi Toda, Keiji Naruse, and Yuki Katanosaka. Elimination of fukutin reveals cellular and molecular pathomechanisms in muscular dystrophy-associated heart failure. Nature Communications, December 2019. URL: http://dx.doi.org/10.1038/s41467-019-13623-2, doi:10.1038/s41467-019-13623-2. This article has 37 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-019-13623-2)